Triglyceride quantification: Following lipid extraction, triglyceride separation and FA transmethylation as previously described (4), samples were injected (2 µl) into an Agilent 7890B gas chromatograph equipped with a Varian CP7420 polar capillary column (100 m; 0.25-mm internal diameter; 0.23-µm thickness) coupled with a 5977A detector. The GC-MS was operated in positive chemical ionization mode with ammonia as reagent gas and high-purity helium as carrier gas at a constant flow rate of 0.44 ml/min under the following conditions: 190°C for 25 min and increased by 1.5°C/min until 245°C. Quantification was achieved by the addition of mixed internal and external standards, in nmol: 50 C 4 ]palmitoylcarnitine and were extracted consecutively with ethyl acetate, ether and methanol. The supernatants were combined and then concentrated to a final volume of 40 µl under a stream of nitrogen gas. Subsequently, 2 µl was injected onto an HPLC (Atlantis dC18 silica column (50 mm x 4.6 mm, particle size 3 µM, Waters) coupled to a 6460 Triple Quadrupole MS/MS system equipped with an ESI Jet Stream source (Agilent Technologies). Chromatographic separation was achieved using a gradient of solvent A (water/0.2% formic acid/10 mM ammonium formate) and B (acetone/0.2% formic acid) as follows: (i) 100% solvent A for 4.5 min; (ii) a linear gradient of solvent B that reached 50% at 33 min and then increased to 100% from 33 min to 54 min; and (iii) 100% solvent A for 6 min to re-equilibrate the column. The flow rate was maintained at 0.5 ml/min throughout. Data were monitored in positive dynamic MRM mode (dMRM) for parent ions of m/z 85 and processed by Mass Hunter QQQ quantitative software (version B.06). Semi-quantitative analysis was performed for carnitine and each acylcarnitine by normalizing to the selected internal standard. Supplemental Table 2 provides a list of all internal standards used, acylcarnitine compounds measured as well as retention times and coefficient of variations. *Analytes were also detected in MRM transition > 60. ISTD, internal standard; RT, retention time.
Supplementary
Within-CV (coefficient of variation) represents 5 separated extractions analyzed during the same day. Supplementary Figure 1 . Protocol timeline to follow all measures over time until the end of the protocol (week 15) as well as the different measures relative to either isolated heart experiments (ex vivo) or in vivo cardiac function analysis. While metabolic flux analysis was performed on hearts from fed mice freeze-clamped following ex vivo heart perfusion, all the other analysis, including mRNA analysis, immunoblot analysis and TG quantification, were performed on hearts freeze-clamped after analysis of cardiac function in vivo in fed mice. Nutritional status, either fed or fasting, is also indicated in the figure. Figure 4 . Indicators of heart insulin resistance. Representative images (left panel) and quantitation (histograms) of basal (A) IRS-1, (B) phospho-AKT (P-Ser473), AKT and (C) PTP1B immunoreactivity in non-perfused hearts from fed mice and without prior insulin injection. Data are mean± SE (n=4) and normalized to β-actin immunoreactivity. Supplementary Figure 5 . Plasma short-chain and medium-chain acylcarnitines. Plasma (A) shortchain (C2, C3, C4, C5) and (B) medium-chain (C6, C8, C10, C10:1, C12) acylcarnitines were determine (n=4). Data are mean ± SE.
Supplementary Figure 2. Indicators of gluconeogenesis. (A)

Supplementary Figure 6. Glucose metabolism. (A)
Rates of lactate efflux from cytosolic glycolysis of exogenous glucose (n=3-4). (B) Relative contribution of exogenous glucose to acetyl-CoA formation for citrate synthesis (n=4-6). mRNA levels of (C) glucose transporters (GLUT1, GLUT4) and (D) enzymes involved in glucose glycolysis and oxidation (PFK1, PFK2, PDK4; n=4-8) assessed in non-perfused hearts from fed mice. mRNA levels were normalized to those of the housekeeping gene CycA. 
